Natco Pharma (Canada) Inc. v. Canada (Health), 2020 FC 788
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Federal Court (Canada) |
| Citation | 2020 FC 788 |
| Date | 24 July 2020 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
8 practice notes
-
Catalyst Pharmaceuticals, Inc. v. Canada (Attorney General), 2022 FC 292
...reference products are irrelevant (the Applicants’ Memorandum of Fact and Law citing Natco Pharma (Canada) Inc v Canada (Health), 2020 FC 788). (b) The Respondent the Attorney General of Canada [144] The AGC responds that the OSIP (1) reasonably interpreted the data protection provis......
-
AbbVie Corporation v. Canada (Health), 2022 FC 1209
...“another drug”. Citing Justice Nicholas McHaffie’s decision in Natco Pharma (Canada) Inc v Canada (Health), 2020 FC 788, the Minister held at paragraph 54 of the decision that the “indirect” language was to capture a situation where a generic company seeks......
-
Direct Or Indirect Comparison: Reliance On Innovative Drug Data Key To Engaging Data Protection
...Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, providing useful guidance on circumstances under which data protection under the Food and Drugs Regulations ("FDR") may be engaged. In particular, the Court commented on when the data protection provisio......
-
Data Protection Upheld For Subsequently Approved Combination Drugs Containing New Chemical Entities: Federal Court Finds Minister Of Health's Decision To Deny Generic ANDS Filing Is Reasonable
...Link to decision: Natco Pharma (Canada) Inc v Minister of Health and Attorney General of Canada and Gilead Sciences Canada Inc , 2020 FC 788 Originally published 06 August, About Norton Rose Fulbright Canada LLP Norton Rose Fulbright is a global law firm. We provide the world's preeminent c......
Request a trial to view additional results
2 cases
-
Catalyst Pharmaceuticals, Inc. v. Canada (Attorney General), 2022 FC 292
...reference products are irrelevant (the Applicants’ Memorandum of Fact and Law citing Natco Pharma (Canada) Inc v Canada (Health), 2020 FC 788). (b) The Respondent the Attorney General of Canada [144] The AGC responds that the OSIP (1) reasonably interpreted the data protection provis......
-
AbbVie Corporation v. Canada (Health), 2022 FC 1209
...“another drug”. Citing Justice Nicholas McHaffie’s decision in Natco Pharma (Canada) Inc v Canada (Health), 2020 FC 788, the Minister held at paragraph 54 of the decision that the “indirect” language was to capture a situation where a generic company seeks......
6 firm's commentaries
-
Direct Or Indirect Comparison: Reliance On Innovative Drug Data Key To Engaging Data Protection
...Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, providing useful guidance on circumstances under which data protection under the Food and Drugs Regulations ("FDR") may be engaged. In particular, the Court commented on when the data protection provisio......
-
Data Protection Upheld For Subsequently Approved Combination Drugs Containing New Chemical Entities: Federal Court Finds Minister Of Health's Decision To Deny Generic ANDS Filing Is Reasonable
...Link to decision: Natco Pharma (Canada) Inc v Minister of Health and Attorney General of Canada and Gilead Sciences Canada Inc , 2020 FC 788 Originally published 06 August, About Norton Rose Fulbright Canada LLP Norton Rose Fulbright is a global law firm. We provide the world's preeminent c......
-
Heath Canada Reasonable In Finding Natco's Indirect Comparison To GENVOYA Triggered Data Protection
...alafenamide hemifurate (TAF) / emtricitabine product in view of data protection was reasonable: Natco v Minister of Health and Gilead, 2020 FC 788. Specifically, the Federal found that it was reasonable for Health Canada to find that data protection precluded the filing of Natco's ANDS for ......
-
Health Canada reasonable in finding Natco’s indirect comparison to GENVOYA triggered data protection
...alafenamide hemifurate (TAF) / emtricitabine product in view of data protection was reasonable: Natco v Minister of Health and Gilead, 2020 FC 788. Specifically, the Federal Court found that it was reasonable for Health Canada to find that data protection precluded the filing of Natco’s AND......
Request a trial to view additional results